Table 3.
Respiratory outcomes at one-year corrected age by treatment group.
| Follow-up cohort | Late surfactant | Control | Relative benefit (95% CI) | ||
|---|---|---|---|---|---|
| No pulmonary morbidity | 110/439 (25.1) | 59/210 (28.1) | 51/229 (22.3) | 1.27 (0.89, 1.81) | |
| Persistent pulmonary morbidity | 153/426 (35.9) | 74/208 (35.6) | 79/218 (36.2) | 1.01 (0.87, 1.17) | |
| Wheezing phenotype | |||||
| Dichotomous | Any | 291/436 (66.7) | 140/210 (66.7) | 151/226 (66.8) | 0.99 (0.74, 1.31) |
| Ordered* | Inhaled corticosteroid ± bronchodilator | 134/436 (30.7) | 66/210 (31.4) | 68/226 (30.1) | |
| Bronchodilator ± wheeze | 108/436 (24.8) | 51/210 (24.3) | 57/226 (25.2) | ||
| Wheeze only | 49/436 (11.2) | 23/210 (11.0) | 26/226 (11.5) | ||
| None | 145/436 (33.3) | 70/210 (33.3) | 75/226 (33.3) | ||
| Post-discharge morbidity domains | Respiratory hospitalization | 121/428 (28.3) | 60/205 (29.3) | 61/223 (27.4) | 0.97 (0.85, 1.10) |
| Home respiratory support | 198/431 (45.9) | 80/208 (38.5) | 118/223 (52.9) | 1.28 (1.07, 1.55) | |
| Any respiratory medication exposure | 277/438 (63.2) | 132/211 (62.6) | 145 (63.9) | 1.07 (0.82, 1.40) | |
| Post-discharge medication use | Diuretic | 89/430 (20.7) | 40/207 (19.3) | 49/223 (22.0) | 1.04 (0.94, 1.15) |
| Bronchodilator | 221/435 (50.8) | 110/210 (52.4) | 111/225 (49.3) | 0.95 (0.77, 1.16) | |
| Inhaled corticosteroid | 134/430 (31.2) | 66/208 (31.7) | 68/222 (30.6) | 0.99 (0.87, 1.13) | |
| Systemic steroid | 70/430 (16.3) | 37/208 (17.8) | 33/222 (16.3) | 0.97 (0.89, 1.06) |
Data are n/N (%) and Relative benefit (95% confidence interval)
Relative benefit by generalized estimating equation, accounting for clustering of siblings
*
P value 0.97 by chi-square